Lymphoma Stem Cell Therapy Development

Lymphoma is a malignant tumor originating from the lymphatic hematopoietic system. Depending on the tumor cells, the disease can be divided into non-Hodgkin's lymphoma and Hodgkin's lymphoma. Lymphomas are highly heterogeneous, and treatment outcomes vary greatly. CD BioSciences is offering lymphoma stem cell therapy development services to facilitate the development of treatments for this disease.

Overview of Lymphoma

The body's one line of defense against microorganisms, the lymphatic system, is where lymphoma, a particular type of cancer, develops. The lymph nodes, spleen, thymus, and bone marrow are all parts of the lymphatic system. All of these locations as well as other organs throughout the body could be impacted by lymphoma. Since the body contains lymphatic tissue all over, lymphomas that develop in various places present with various symptoms.

Stem Cells Transplantation in Lymphoma Treatment

Patients who need to endure higher chemotherapy doses to help completely eradicate their tumors may be able to do so through stem cell transplantation. Autologous stem cell transplants and allogeneic stem cell transplants can be distinguished based on where the stem cells came from. Because they have fewer side effects, autologous stem cell transplants are more frequently used to treat lymphoma of these. Only a small number of lymphoma patients are currently being treated with stem cell transplantation due to the complexity of the procedure, though this number is rising.

Stem Cell as Vehicles of Antibody in Tumor Treatment

Stem cells are frequently used as delivery systems in cell-based anti-tumor therapy due to their homing capacity and ease of genetic modification. In addition to maintaining their biological characteristics, they have the ability to secrete anti-tumor agents continuously into the tumor environment, which will eventually kill the tumor cells more effectively. After infection by viral or non-viral vectors which carry genes of antitumor agents, engineered stem cells release a wide variety of therapeutic drugs, for example, therapeutic proteins (TRAIL, IFN), interleukin (IL), oncolytic viruses, prodrugs, apoptosis-inducing agents, anti-angiogenic factors.

• Improving the Homing Characteristics of Stem Cells
  A study demonstrated that to create PPG-MSCs, vascular cell adhesion molecule-1 (VCAM-1) antibody (Ab-VCAM-1) was coated onto mesenchymal stem cells (MSCs), and the PPG-MSCs were then co-incubated with the Ab-VCAM-1-MSCs complex to form AbVCAM-1-MSCs complex, causing MSCs to secrete AbVCAM. As a result, MSCs' capacity for migration can be increased. Stem cells now have the option to specifically target a variety of tumors thanks to antibody coating technology. In gene therapy, MSCs and NSCs are both frequently used as delivery systems. They could prove to be a fruitful option for cell carriers in targeted cancer therapy.

Stem cell-based agents delivery strategies. (Wei, Z. Y. et al. 2021)

Our Services

CD BioSciences offers lymphoma stem cell therapy development services. Lymphoma is a heterogeneous malignancy and its incidence is increasing in the past decades all over the world. Stem cell-based related therapies offer new ideas for the treatment of lymphoma.

As a pioneer in biotechnology, CD BioSciences has grown into one of the largest independent biotechnology companies in the world. CD BioSciences is committed to providing professional and efficient service to our customers around the world. If you are interested in our service, please contact us.

Reference

1. Wei, Z. Y. et al. (2021). Stem cell as vehicles of antibody in treatment of lymphoma: a novel and potential targeted therapy. Stem cell reviews and Reports. 17(3).